Medication adherence is an ongoing and serious problem; according to the Center for Health Transformation, the annual cost of patients not taking their medicines as prescribed is nearly $300 billion, with approximately 125,000 patients dying each year due to poor adherence-that’s 342 people every day.
Medication adherence is an ongoing and serious problem; according to the Center for Health Transformation, the annual cost of patients not taking their medicines as prescribed is nearly $300 billion, with approximately 125,000 patients dying each year due to poor adherence-that’s 342 people every day.
Improving adherence rates in the United States has been a focus of manufacturers, payers and providers for well over 10 years, yet poor adherence continues to persist. But now, with broader support for and focus on improved outcomes, will the right incentives finally be in place to make a notable shift in adherence rates?
Last October, Pharm Exec convened a Round Table discussion on the subject with expert stakeholders from the National Consumers League, the Midwest Business Group on Health, IPSOS Health, Merck, Aetna, and others. And last August, Pharm Exec ran an extensive article on adherence, exploring new theories and tactics for tackling the issue.
As part of the continuation of this ongoing conversation, the Center for Business Intelligence will be hosting its 11th annual Patient Adherence Forum April 26-27 in Philadelphia. The conference will highlight how the changes of healthcare reform, technological innovation, and a patient-centered healthcare conversation can help biopharmaceutical manufactures improve adherence. Panels and discussions will explore new approaches to influencing patient behavior, showcase successful case studies, and provides actionable strategies to implement in adherence efforts.
Featured speakers at this year’s conference include:
• William H. Shrank, M.D., MSHS, Director, Rapid Cycle Evaluation Group, Center for Medicare and Medicaid Service Innovation – providing the CMS opening keynote address;
• Sabrina LeBlanc, Vice President, Innovation and Program Development, Weight Watchers – providing the cross-industry keynote address;
• D. Stuart Sowder, Pharm.D., J.D., MBA, Vice President, External Medical Communications, Pfizer – 2011 Pharm Exec Emerging Leader; and
• Bruce Sherman, M.D., FCCP, FACOEM, Medical Director, Employers Health Coalition (and Assistant Clinical Professor, Department of Medicine, Case Western Reserve University) – providing physician perspective
Additionally, the conference will feature the 7th Annual Strategic Patient Adherence Awards, which recognizes innovative adherence programs at various companies and organizations in various categories: payer/PBM, employer, manufacturer, pharmacy, and scientific. The winners will be announced at the SPA Awards Gala Luncheon on Thursday, April 26.
Attendees at this year’s Patient Adherence Forum can expect to set realistic expectations internally with qualitative benchmarking data and tested metrics; hear case studies examining how biopharmaceutical companies can engage patients, physicians, pharmacists, employers, and payers in adherence and persistency promoting practices; and take part in interactive panel discussions, working groups, and roundtables to stimulate collaboration and innovation. Please click here for more information and to register for this event.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.